Skip to main content

Research Studies

Division of Developmental and Behavioral Pediatrics Research Studies

Find research studies available to children cared for by the Division of Developmental and Behavioral Pediatrics team.

Contact us

Study categories

Eligible age

BUFFET-Snack: Food Selectivity Study for Autistic Youth

The Building Up Food Flexibility and Exposure Treatment (BUFFET) program helps autistic children 8-12 years old to be more flexible with trying new or non-preferred foods. BUFFET-Snack is a brief version of this treatment program. The goal of this study is to see if families can complete BUFFET-Snack and if they like it. BUFFET-Snack is a cognitive behavioral therapy. It will be a good fit for children who can communicate with full sentences and have some back-and-forth conversation skills.

Phase: Pilot

Actively recruiting: Yes

Category: Children

ML-004 for Adolescents and Adults With ASD

The purpose of this study is to test the safety of an investigational medicine called ML-004 and how it might affect communication, behavior, and other symptoms of autism spectrum disorder (ASD). This medication is investigational because it has not been approved by the FDA for the treatment of symptoms associated with autism.

You may qualify if you:

  • Are 12 to 17 years old
  • Have an autism diagnosis
  • Have a designated care/study partner able to attend every visit and answer questions about the participant. This person does not need to be the participant's parent or guardian. This person should have significant contact with them and can support them for the duration of the study.
  • Are able to swallow the study medication (tablet)

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children

Pimavanserin for the Treatment of Irritability Associated With ASD

The purpose of this study is to test an investigational medication in children and adolescents aged 5-17 years old with irritability associated with autism spectrum disorder (ASD). The name of the medication being tested in this study is pimavanserin. This medication is investigational because it has not been approved by the FDA for the treatment of irritability associated with autism. The main risks of this study are from the medication, which include nausea, dizziness, and sleepiness.

Phase: Phase II

Actively recruiting: No

Category: Children

Jump back to top